NCT05877430View on ClinicalTrials.gov

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2027

Conditions
NSCLCHNSCCMelanomaMetastatic CancerAdvanced Solid TumorAdvanced Cancer
Interventions
DRUG

CJRB-101

In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.

DRUG

Pembrolizumab injection

200 mg given by intravenous (IV) infusion once every 3 weeks

Trial Locations (4)

15260

RECRUITING

University of Pittsburgh, Pittsburgh

92697

RECRUITING

University of California, Irvine, Irvine

Unknown

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

CJ Bioscience, Inc.

INDUSTRY